Table 3.
Number of infections averted via pre-exposure prophylaxis (PrEP) use (2015–2032) in comparison to no PrEP.
| Cumulative starters | Consistent use (%) |
||||
|---|---|---|---|---|---|
| 10% | 20% | 30% | 40% | 50% | |
| 120,000 | 995 (1.9%) | 1355 (2.5%) | 1680 (3.1%) | 2075 (3.9%) | 2405 (4.5%) |
| 100,000 | 810 (1.5%) | 1120 (2.1%) | 1365 (2.5%) | 1675 (3.1%) | 1955 (3.6%) |
| 80,000 | 675 (1.3%) | 895 (1.7%) | 1100 (2.0%) | 1330 (2.5%) | 1540 (2.9%) |
| 60,000 | 525 (1.0%) | 695 (1.3%) | 840 (1.6%) | 1025 (1.9%) | 1160 (2.2%) |
| 40,000 | 370 (0.7%) | 455 (0.8%) | 530 (1.0%) | 635 (1.2%) | 710 (1.3%) |
The analysis are stratified by percentage of users using PrEP consistently from 2021 onwards. We defined consistent use as daily PrEP use with 95% effectiveness of PrEP, with high retention (average duration of five years) in the PrEP programs. Non-consistent PrEP use has an effectiveness of 85%.